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MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression post-transcriptionally. miRNAs can be
induced by a variety of stresses such as hypoxia, and are involved in diverse biological processes including differentiation,
cell proliferation, cell death, and tumorigenesis. Hypoxia, a common feature of tumor microenvironment, can
induce a number of miRNAs expression. miRNA-210 (miR-210) is one of the hypoxia-regulated-miRNAs, which
has been investigated extensively in cancer. However, paradoxically opposing results were documented regarding
whether it is an oncogene or a tumor suppressor, and whether it is a positive or negative prognostic biomarker.
In the present review, we focus on the following investigations of miR-210: 1) its functions of as an oncogene,
2) its functions as a tumor suppressor, 3) its functions in mitochondrial metabolism, and finally, the diagnostic and
prognostic value of miR-210 in cancer researches.
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MicroRNAs (miRNAs) are small noncoding RNAs that
regulate gene expression post-transcriptionally by pairing
to 3’ untranslated regions (UTRs), coding sequences or 5’
UTRs of target messenger RNAs (mRNAs), which in most
cases leads to translation inhibition or mRNA degradation
[1]. In mammals, miRNAs are predicted to regulate the
activity of approximately 50% of all protein-coding genes
[2]. Due to the widespread regulating functions, miRNAs
are involved in almost every cellular process including
differentiation, cell proliferation, cell death, and tumori-
genesis [3].
Hypoxia is a common feature of the tumor microenvir-
onment [4] and has been an extensively investigated field
in cancer researches demonstrating its critical role in vari-
ous physiologic and pathologic processes including cell
proliferation, cell survival, angiogenesis, metabolism, tumor
invasion and metastasis [5]. It is widely accepted that
hypoxia represents an independent adverse prognostic
factor in many tumor types [4,6].* Correspondence: Baoshli@yahoo.com
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unless otherwise stated.Since the first article demonstrated the functional link
between hypoxia and miRNAs expression, which identi-
fied a specific hypoxia-regulated miRNAs (HRMs) playing
an important role in cell survival in low oxygen environ-
ment [7], that more and more HRMs were identified
[8-12]. Although discrepancies exist among HRMs iden-
tified by different research groups, the up-regulation of
miR-210 induced by hypoxia has been consistent in all
published studies in both normal and transformed cells,
which implies an essential role of miR-210 for cell adapta-
tion to hypoxia [13-15]. Not only in vitro studies corre-
lated miR-210 with hypoxia, in vivo investigation also
verified it. In tumor tissues such as breast cancer and head
and neck cancers, miR-210 expression levels have been
demonstrated to be correlated with hypoxia gene sig-
natures, which suggested a direct connection between
miR-210 expression and hypoxia [16,17].
miR-210 is an intronic miRNA located within the
genomic loci of transcript AK123483 [18]. While most
studies reported miR-210 regulation in a hypoxia-inducible
factor-1 (HIF-1)-dependent way [19-21], HIF-2-dependent
[22,23] and HIF-independent [24,25] regulation of miR-210
have also been reported. The master HRM miR-210 has
been investigated intensively, which has identified a variety
of functionally important targets involved in cell cycle. This is an Open Access article distributed under the terms of the Creative
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[37-40], angiogenesis [41-51] as well as metabolism [52-57].
However, paradoxically opposing results were documen-
ted with regard to whether miR-210 is an oncogene or a
tumor suppressor, and whether it is a positive or negative
prognostic biomarker. In the present review, we focus on
the following investigations of miR-210: 1) its functions of
as an oncogene, 2) its functions as a tumor suppressor, 3)
its functions in mitochondrial metabolism, and finally,
the diagnostic and prognostic value of miR-210 in cancer
researches.
miR-210 functions as an oncogene
Since miR-210 is up-regulated ubiquitously and robustly
in hypoxic cells and hypoxia is a key feature of solid
tumors, it is reasonable to explore the functions of
miR-210 in tumorigenesis. With the development of
bioinformatic miRNA targets prediction tools as well as the
improvement of experimental approaches, many diverseTable 1 Targets of miR-210 functioning as oncogene
Symbol Description
MNT [22] MAX network transcriptional repressor
Casp8ap2 [31] Caspase 8 associated protein 2
PTBP3/ROD1 [61] Polypyrimidine tract binding protein
3/Regulator of differentiation 1
E2F3 [32] E2F transcription factor 3
BNIP3 [36] BCL2/adenovirus E1B 19 kDa interacting protein 3
AIFM3 [27] Apoptosis inducing factor, mitochondrion
associated, 3
EFNA3 [41,64] Ephrin-A3
VMP1 [42] Vacuole membrane protein 1
RAD52 [66] RAD52 homolog (S. cerevisiae)
PTPN1 [68] protein tyrosine phosphatase,
non-receptor type 1
HOXA1 [68] Homeobox A1
TP53I11 [68] tumor protein p53 inducible protein 11
Abbreviations: MSC mesenchymal stem cell, HPASMC human pulmonary artery smoo
endothelial cell.targets of miR-210 have been identified, revealing an im-
portant role of miR-210 in tumor initiation and progres-
sion [58]. Table 1 presents the identified targets of
miR-210, showing the oncogenic role of miR-210.
miR-210 promotes cancer cell proliferation
Sustaining proliferative capacity is a key hallmark of
cancer cells which acquire such capacity through a num-
ber of ways: 1) they may produce growth factor ligands
themselves and stimulate normal cells in tumor-associated
stroma to supply various growth factors, 2) they may har-
bor activating mutations to sustain proliferative signaling,
and 3) they may disrupt negative-feedback loops that
attenuate proliferative signaling [59].
Over the past few years, the role of hypoxia-inducible
miR-210 in cell cycle regulation has been a subject of
considerable interest and has provided reliable evidence
supporting a role for miR-210 in promoting cancer cell
proliferation [18,21,22,26-30]. Zhang and colleagues [22]Related function Involved cell type

















Regulate migration and invasion SMMC-7721
HuH-7
Involve in DNA repair HeLa
MCF-7
Regulate immune response IGR-Heu
NA-8
Regulate immune response IGR-Heu
NA-8
Regulate immune response IGR-Heu
NA-8
th muscle cell, NPCs neural progenitor cell, HUVEC human umbilical vein
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target. Overexpression of miR-210 can override hypoxia-
induced cancer cell cycle arrest and promote cell prolif-
eration by down-regulating MNT directly and activating
c-MYC indirectly. Similarly but in a different way, Yang
and colleagues [27] demonstrated that downregulation
of miR-210 in hypoxic human hepatoma cells induced
cell cycle arrest in the G0/G1, resulting in reduced
cancer cell proliferation. However, functional targets
of miR-210 contributing to such effect require further
researches.
miR-210 inhibits apoptosis and protects cancer cell
Hypoxic cancer cells are notorious for their resistance to
radiotherapy and many conventional chemotherapeutic
agents, of which the underlying mechanisms remain to
be revealed [3]. As the master HRM, the association of
miR-210 and apoptosis as well as cell survival was inten-
sively investigated. Its antiapoptotic and cytoprotective
effects have been demonstrated in many studies involving
not only cancer cells [27,60,61] but also normal cells
such as human pulmonary artery smooth muscle cells
(HPASMC) [32], cardiomyocytes [24,33], bone marrow-
derived mesenchymal stem cells (MSCs) [31], as well as
neural progenitor cells [36].
Many functional targets of miR-210 associated with
apoptosis have been identified, as shown in Table 1. By
downregulating the expression of caspase-8-associated
protein-2 (Casp8ap2), miR-210 promoted the survival of
MSCs that underwent ischemic preconditioning [31].
Through repressing the expression of regulator of differ-
entiation 1 (ROD1), which is also named polypyrimidine
tract binding protein 3 (PTBP3), miR-210 reduced the
apoptosis of hypoxic cells and increased the survival of
hypoxic cells [61]. E2F3, a member of the E2F family
of transcriptional factors and a well-known cell cycle
regulator, was identified as a direct target of miR-210
in hypoxic HPASMC, its downregulation was shown
to be responsible in part for the antiapoptotic effect
of miR-210 [32]. Knock down of miR-210 in hypoxic
HPASMC, which resulted in concomitant upregulation of
E2F3, induced apoptosis without significant change of cell
proliferation, indicating the proapoptotic effect of E2F3 as
well as the antiapoptotic effect of miR-210 in HPASMC
under hypoxia stress [32]. The cytoprotective effect of
miR-210 against radiotherapy was also investigated. Over-
expression of miR-210 in A549 cell line (non-small cell
lung carcinoma-derived cell line) under normoxia can
protect cancer cells from radiation [57], while downregu-
lation of miR-210 in hypoxic human hepatoma cells led to
increased radiosensitivity, both in vitro and in vivo [27,62].
As elucidated by Grosso et al., A549 cells stably expressing
miR-210 in normoxia exhibited similar radioresistance
to A549 cells expressing miR-control in hypoxia, andhypoxia can further increase this resistance. Although
the underlying mechanisms responsible for this radio-
resistance were not fully investigated, the authors gave
us a clue that miR-210 expressing cells showed rapid
repair of DNA double-strand breaks (DSBs), which
might contribute to radioresistance [57]. In addition,
synthetic miRNA-Mowers targeting miR-210 in bladder
cancer cells can inhibit growth and migration and induce
apoptosis [60].
miR-210 regulates angiogenesis, promotes invasion and
metastasis
Inducing angiogenesis is another hallmark of cancer,
which not only provides nutrients and oxygen, evacuates
metabolic wastes and carbon dioxide to sustain cancer
cells, but also facilitates metastasis [59]. Many miRNAs
have been involved in tumor angiogenesis [44,63], inclu-
ding miR-21, miR-106a, miR-126, miR-155, miR-182,
miR-210 and miR-424.
miR-210 overexpression in normoxic endothelial cells
stimulated the formation of capillary-like structures and
vascular endothelial growth factor-driven cell migration,
while blockade had the opposite effect [41]. Ephrin-A3
(EFNA3) was identified as the direct target, whose down-
modulation was necessary for miR-210 mediated stimula-
tion of both tubulogenesis and chemotaxis [41]. Notably,
hypoxia can increase the expression of EFNA3 mRNA, so
the down-modulation of EFNA3 may attribute to transla-
tion inhibition [41]. Another study confirmed EFNA3 as a
direct target of miR-210 through luciferase assay, however,
upregulation of EFNA3 was shown in ischemia brain,
which seemed to be contradictory with the hypothesis that
hypoxia induced miR-210 expression would result in
downregulation of EFNA3 [64]. Apparently, the unpre-
dictable effects of miR-210 on the expression of EFNA3
need further investigation.
In hypoxic hepatocellular carcinoma (HCC), vacuole
membrane protein 1 (VMP1) was identified as the direct
and functional downstream target of miR-210, which me-
diates hypoxia-induced HCC cell migration and invasion
[42]. Overexpression of miR-210 in non-invading breast
cancer cell line MCF-7 cells led to cell invasion while
repression of miR-210 in migrating and invading breast
cell line MDA-MB-231 cells resulted in decreased cell mi-
gration and invasion [49]. Meanwhile, miR-210 contained
in exosomes released by cancer cells can be transported to
endothelial cells to induce angiogenesis [50].
miR-210 involves in DNA repair
Genome integrity is of vital importance for normal
cells since mutations of crucial genes result in multiple
diseases including cancer. Various stresses, including mu-
tagens, ROS, ultraviolet light, radiation as well as chemo-
therapeutic agents can induce DNA damage, of which
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effect [65].
Cancer is characterized by genomic instability [59],
which may result from hypoxic tumor microenvironment
by affecting DNA repair capacity of cancer cells [5].
RAD52, a protein important for DNA DSB repair and
homologous recombination, has been identified as a
functional target of miR-210 [66]. In addition to down-
regulating DNA repair genes, such as RAD52, to increase
genomic instability which confers aggressiveness to cancer
cells, miR-210 appears to be capable of facilitating DNA
DSB repair after radiation exposure, which makes cancer
cells more intractable, as demonstrated by Grosso et al.
[57]. NSCLC cell lines expressing miR-210 in normoxia
are more resistant to radiation due to more effective DNA
repair, of which the underlying mechanism remains to
be elucidated.
miR-210 induces immunosuppression
During the initiation and development of cancer, cancer
cells have acquired multiple mechanisms to evade im-
munological surveillance. Emerging evidence has shown
that certain miRNAs regulate expression of genes that
are critically involved in both innate and adaptive immune
responses [67]. A recent study investigated the role of
miR-210, up-expressed in the hypoxic zones of human
tumor tissues, in inducing immunosuppression in hypoxicTable 2 Targets of miR-210 functioning as tumor suppressor
Symbol Description
E2F3 [18,21] E2F transcription factor 3
FGFRL1 [19,26] fibroblast growth factor receptor-like 1
PTPN2 [30] protein tyrosine phosphatase, non-receptor type 2
PIK1 [29] 1-phosphatidylinositol 4-kinase
Cdc25B [29] cell division cycle 25B
Bub1B [29] BUB1 mitotic checkpoint serine/threonine kinase B
CCNF [29] cyclin F
Fam83D [29] family with sequence similarity 83, member D
Bcl-2 [34] B-cell CLL/lymphoma 2
Abbreviations: ASC adipose-derived stem cell.cancer cells [68]. They examined the susceptibility of
IGR-Heu (human NSCLC cell line) and NA-8 (human
melanoma cell line) cells in which miR-210 expression
had been abrogated by anti-miR-210 to cytotoxic T cells
(CTC)-mediated lysis under hypoxia, demonstrated that
these cancer cells were more susceptible to CTC-mediated
lysis, implying the immunosuppressive effects of miR-210
in hypoxic cancer cells. Functional analysis has identi-
fied the potential targets of miR-210, including PTPN1,
HOXA1 and TP53I11 that confer immunosuppression to
hypoxic cells [68].
miR-210 functions as a tumor suppressor
Controversial to the above cited multiple studies showing
that miR-210 acts as an oncogene, many studies suggest
that miR-210 can also act as a tumor suppressor, inhibit-
ing tumor initiation. Table 2 summarizes the identified
targets of miR-210, implying its potential role as tumor
suppressor.
miR-210 induces cell cycle arrest, inhibits cell proliferation,
promotes apoptosis
In the study conducted by Giannakakis et al. [18], they
found that miR-210 was deleted in 50% of ovarian can-
cer cell lines and 64% of ovarian cancer samples tested,
implying miR-210 as a potential tumor suppressor gene.
Subsequent functional analysis identified several targetsgene
Related function Involved cell type





Regulate cell proliferation MCF10A
KYSE-170
KYSE-590
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going evidence of proapoptotic effect of E2F3 in hypoxia
HPASMC, E2F3 was considered as a promoter of cell pro-
liferaion here. Overexpression of miR-210 down-regulated
E2F3 expression at the translational level, suggesting that
down-regulation of miR-210 expression (such as demon-
strated in ovarian cancer due to gene copy aberrations)
in hypoxia may increase the expression of E2F3 that
promotes cell proliferation and involves in tumorigen-
esis [18]. However, considering that E2F3 comprises
two functionally different forms, E2F3a and E2F3b,
with the same 3’ UTR, both E2F3a and E2F3b are
targets of miR-210 [18], this interpretation warrants
more experiments.
Tsuchiya et al. [26] also demonstrated the anti-prolife-
rative role of miR-210 in cancer. They reported the down-
expression of miR-210 in human esophageal squamous
cell carcinoma (ESCC) and derived cell lines, and elu-
cidated that overexpression of miR-210 in KYSE-170
(ESCC) cell line not only induces cell cycle arrest in
both G0/G1 and G2/M phases, but also causes cell
apoptosis and necrosis. Functional analysis identified
fibroblast growth factor receptor-like 1 (FGFRL1) as the
direct target.
Additional evidence has implicated miR-210 in mitotic
regulation. In CNE cells treated with hypoxia mimetic
agent, over-expression of exogenous miR-210 significantly
decreased cell proliferation, and vice versa [29]. Molecular
mechanism analysis revealed that a group of mitosis-
related genes, including Plk1, Cdc25B, Cyclin F, Bulb1B
and Fam83D, are the direct targets of miR-210, suggesting
its inhibitory role on tumor formation.
In addition to inhibiting apoptosis as shown previ-
ously, miR-210 can mediate hypoxia-induced apoptosis
at least in neuroblastoma cells as demonstrated by Chio
et al. [34]. They treated neuro-2a (neuroblastoma cell
line) cells with oxygen/glucose deprivation (OGD), eluci-
dated the important role of miR-210 in OGD-induced
cell apoptosis, and identified Bcl-2 as the functional
target. Overexpression of miR-210 decreased the mRNA
and protein levels of Bcl-2, an anti-apoptotic gene, result-
ing in increased apoptosis.
miR-210 and mitochondrial metabolism
Under hypoxic conditions, cell metabolism shifts from
mitochondrial oxidative phosphorylation to glycolysis
(the Pasteur effect). HIF-1 plays a critical role in this
effect, by up-regulating the expression of most glyco-
lytic enzymes as well as pyruvate dehydrogenase kin-
ase, while down-regulating mitochondrial respiration
[69]. As tumors largely rely on glycolysis even under
normal oxygen supply (Warburg effect) [59,70] which
is significantly different from normal cells, the underling
molecular mechanisms deserve further investigation.The regulation of mitochondrial metabolism during
hypoxia by miR-210 was first reported by Chan et al.
[52]. They utilized pulmonary arterial endothelial cells
as a representative hypoxic cell type, demonstrated that
miR-210 directly targets iron-sulfur cluster assembly pro-
teins (ISCU1/2) and decreases the activity of prototypical
iron-sulfur proteins controlling mitochondrial metab-
olism, including ComplexIand acontiase, resulting in
decreased oxidative phosphorylation. Subsequent studies
investigating the role of miR-210 in modulating mito-
chondrial function have revealed more targets of miR-210
[53-57]. Besides ISCU [54], which was further confirmed,
GPD1L [20], COX10 [53], SDHD and NDUFA4 [55] were
also identified as direct targets involved in mitochondrial
function regulation. In the study by Puissegur et al. [55],
A549 cells overexpressing miR-210 exhibited an aberrant
mitochondrial phenotype, mRNA expression profiling
analysis linked miR-210 to mitochondrial dysfunction. In-
terestingly, miR-210 acts not only as a downstream
mediator of HIF-1α, it can also promote HIF-1α stability
by suppressing GPD1L, producing a positive feedback
between HIF-1α and miR-210 [20]. As miR-210 is highly
stable, when hypoxic cells undergo reoxygenation, HIF-1α
is degraded immediately, but miR-210 remains stable to
sustain glycolytic phenotype and inhibit mitochondrial
metabolism under normoxia. Such advantage may be
utilized by cancer cells, contributing to Warburg effect
[57]. Taken together, the above evidence suggests an in-
disputable role of miR-210 in modulating mitochondrial
metabolism, and facilitating adaptation of cancer cells to
hypoxic condition.
miR-210 as diagnostic and prognostic biomarker in cancer
Early diagnosis and prognosis evaluation of cancer are of
vital importance to improve treatment outcome. It is
well acknowledged that cancer cells or tissues harbor
aberrant miRNA expression profiles compared to normal
cells or tissues, and specific miRNA signature can not only
be used for diagnosis but also to classify cancer pa-
tients into subgroups with different prognosis guiding
individualized treatment [71-77]. Many studies have
investigated the role of miR-210 in cancer diagnosis and
prognosis, however, presenting apparently conflicting
results.
Most evidence showed that miR-210 was up-regulated
in many solid tumors, including breast cancer [16,78-80],
head and neck cancer [17,76], pancreatic cancer [81-83],
lung cancer [55,84-87], renal cancer [23,88,89], lymphoma
[90], osteosarcoma [91], esophageal cancer [92] as well as
ovarian cancer [93]. There are also some inconsistent evi-
dence that miR-210 was deleted in some cases of ovarian
cancer [18], and was down-regulated in some cases of
esophageal cancer [26], exhibiting the complexity and het-
erogeneity of cancer.
Table 3 Studies investigating diagnostic value of miR-210
First author Publication year Types of cancer Types of sample Negative controls Sensitivity Specificity
Wang [81] 2009 Pancreatic cancer plasma Healthy controls 53% 78%
Xing [86] 2010 Squamous cell LC sputum Healthy controls 58% 79%
Shen [94] 2011 Lung cancer plasma Benign SPNs 56% 73%
Tan [95] 2011 Squamous cell LC tissue Normal lung tissue Not provided Not provided
Ren [96] 2012 Pancreatic cancer stool Healthy controls 85% 67%
Li [97] 2013 NSCLC sputum Healthy controls Not provided Not provided
Li [98] 2013 NSCLC serum Healthy controls 79% 74%
Zhao [99] 2013 Renal cancer serum Healthy controls 81% 79%
Iwamoto [100] 2014 Renal cancer serum Healthy controls 65% 83%
Abbreviations: LC lung cancer, NSCLC non-small cell lung cancer, SPN solitary pulmonary nodule.
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gating the diagnostic value of miR-210, either alone or
in combination with other miRNAs, providing the sensi-
tivity and specificity of miR-210 when it was used alone
to discriminate cancer from non-cancer. Because of the
inherent stability of miRNAs [101], and the high sensi-
tivity as well as specificity of quantitative RT-PCR [102],
samples used for diagnosis include not only tumor tissue
but also serum, plasma, sputum and stool that are more
available in clinic, showing the promise of miRNAs in
clinical application [103]. Notably, the diagnostic power
increased when using multiple miRNAs instead of only
one miRNA [81,86,94-97]. For example, in the study
conducted by wang et al. [81], they profiled four pancre-
atic cancer related miRNAs (miR-21, miR-210, miR-155,
miR-196a) as blood-based biomarker for diagnosis. TheTable 4 Studies investigating prognostic value of miR-210
First author Publication year Types of cancer
Camps [16] 2008 Breast cancer
Lawrie [90] 2008 Diffuse large B-cell lymphoma
Gee [17] 2010 Head and neck cancer
Greither [82] 2010 Pancreatic cancer
Buffa [107] 2011 Breast cancer (ER−)
Radiojicic [78] 2011 Triple-negative breast cancer
Rothe [80] 2011 Breast cancer
Greither [104] 2012 Soft-tissue sarcoma
Toyama [79] 2012 Breast cancer
Volinia [105] 2012 Breast cancer
Cai [91] 2013 Pediatric osteosarcoma
Eilertsen [87] 2013 Non-small cell lung cancer
McCormick [23] 2013 Renal cancer
Qiu [106] 2013 Glioblastoma
*intermediate VS high expression level.
#stromal cells in tumor tissues.
**low VS high expression level.
Abbreviations: PFS progression-free survival, OS overall survival, RFS relapse-free survsensitivity and specificity were 42% to 53% and 73%
to 89% respectively, when using only one miRNA for
diagnosis, but with the panel of four miRNAs, the sensitiv-
ity and specificity increased to 64% and 89% respect-
ively. Other similar studies also showed us similar
results [86,94-97].
Table 4 lists the studies [16,17,23,78-80,82,87,90,91,104-107]
investigating the prognostic value of miR-210. While most
studies documented that high miR-210 expression level in
tumor tissue or blood was correlated with poor disease-
free and/or overall survival and was a negative prognostic
factor, at least three articles investigating soft-tissue sar-
coma [104], renal cancer [23] and NSCLC [87] respect-
ively, indicated that miR-210 was a positive prognostic
factor. Obviously, the prognostic value of miR-210 expres-















ival, DSS disease-specific survival, ER− estrogen receptor negative.
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Buffa et al. presented us an excellent example for ex-
ploring miRNAs as prognostic factors for cancer. They
conducted comprehensive miRNA and mRNA expression
profiling in a large cohort of 207 early-invasive breast can-
cers. To identify miRNAs with independent prognostic
value, they performed penalized Cox regression for distant
relapse-free survival (DRFS), including all miRNAs, clin-
ical covariates and gene signatures. At last, they detected
four microRNAs to be independently associated with
DRFS in estrogen receptor (ER)-positive and six in ER-
negative (including miR-210) cases. To further confirm
the value of these prognostic miRNAs, they also carried
out correlation analysis of these miRNAs with clinicopath-
ologic factors, indicating that miR-210 expression was
associated with proliferation, ER positivity, grade, and
nodal invasion. In addition, they performed prognostic
analysis of pri-miRNAs and predicted target transcripts of
prognostic miRNAs, as well as miRNA-processing genes,
revealing that identified miRNAs were virtually inde-
pendent prognostic factors. They also demonstrated
that combination of miRNA and target expression could
identify patients with the poorest prognosis, showing us
the prospect of integrating miRNA and mRNA informa-
tion for prognosis analysis.
Conclusions and future directions
As the master HRM, regulated mainly by HIF-1, miR-210
plays an essential role in hypoxic response. In addition to
regulating mitochondrial metabolism, miR-210 is involved
in regulating cell cycle, cell survival, differentiation, DNA
repair as well as immune response.
Since hypoxia can influence both cell death and sur-
vival [108], it is not surprising that miR-210 can act both
as an oncogene and a tumor suppressor, depending on
cellular context, the extent and duration of hypoxia. A
reasonable explanation is that since miRNAs can target
hundreds of mRNAs with differential biological functions,
the ultimate effect of miR-210 depends on the target
mRNAs that are available in certain cells. In addition to
multiple targets discussed in this review, many other genes
have been identified as miR-210 targets, and more and
more potential target genes are emerging [12]. An alterna-
tive possibility may be that miR-210 acts as a tumor sup-
pressor at the beginning of tumorigenesis when hypoxia is
not significant. However, with the progression of tumor,
hypoxia becomes significant, tumor cells evolve, become
resistant to hypoxia and adapt well to highly expressed
miR-210, then miR-210 switches to an oncogene [19,29].
Due to the paradoxical functions of miR-210, more inves-
tigations are warranted before considering it as an effect-
ive therapeutic target in cancer. Future researches should
elucidate the specific context that is responsible for spe-
cific functions of miR-210. In addition, how to integratemultiple functionally different but related targets of one
peculiar miRNA such as miR-210, so as to precisely pre-
dict its functions remains a great challenge.
Besides functions of miR-210, we also reviewed the
diagnostic and prognostic value of it. As described
above, up-regulated miR-210 is not only be detected in
cancer tissues, but also in body fluids. It is feasible to
discriminate cancer from non-cancer with a specific
group of miRNAs including miR-210. However, when it
comes to prognosis, it is far too early to use miR-210
alone as a prognostic factor without dispute, and more
investigations are needed to elucidate the underlying
mechanism of such discrepancy. In future, global ana-
lysis of large cohorts of patients with not only miRNAs
expression profile but also mRNAs expression profile,
even integrated with other genetic information such as
DNA copy number variance, single nucleotide polymor-
phisms, will provide us more insights about significant
prognostic factors as well as novel therapeutic targets.
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